DRW Securities’s Artelo Biosciences ARTL Stock Holding History

DRW Securities’s Portfolio ARTL Stock Details ARTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-5,728	Closed	-$78.9K	–	1241
2025 Q3	$78.9K	Buy	+5,728	New	+$175K	﹤0.01%	1201

Other funds holding ARTL

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RIL

Rothschild Investment LLC Chicago, Illinois $2.68B AUM 34.39% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

DRW Securities's ARTL Position: Q4 2025 in Review

DRW Securities sold out of Artelo Biosciences (ARTL) in Q4 2025, closing a stake of 5,728 shares — an estimated $78.9K sold.

DRW Securities first reported a position in ARTL in Q3 2025 and held it in 1 quarter. The position peaked at $78.9K in Q3 2025. 8 funds tracked by Wall St. Rank hold ARTL as of Q4 2025.

DRW Securities reported no remaining Artelo Biosciences position as of Q4 2025 after selling out during the quarter.
DRW Securities sold 5,728 Artelo Biosciences shares in Q4 2025, an estimated $78.9K.
DRW Securities first reported a position in Artelo Biosciences in Q3 2025 and held it in 1 quarter.
DRW Securities's Artelo Biosciences position peaked at $78.9K in Q3 2025.
8 funds tracked by Wall St. Rank held Artelo Biosciences as of Q4 2025.

Based on DRW Securities's 13F filing for Q4 2025, filed 12 Feb 2026.